Pediatric Oncology Branch:

Hematologic Malignancies 

Front row: L to R: John Molina, Showri Kakumanu, Nirali Shah (PI), Leah Hoffman, Lauren Little; Back row: L to R: Haneen Shalabi, Ekaterina Nikitina, Bonnie Yates, Terri Moore, Dan Lichtenstein; Missing; Katie Graap

The primary goal of the hematologic diseases program is to develop new treatment strategies for hematologic malignancies, the most frequent cancer type in pediatrics. Although cure rates are excellent for many subtypes of childhood leukemia and lymphoma, new approaches are needed to overcome resistance to standard therapies and to decrease treatment-associated sequelae in survivors of pediatric cancer. We conduct collaborative pre-clinical, translational, and clinical trials that focus on developing targeted agents and applying immunotherapy to direct anti-tumor responses for childhood leukemias and lymphomas.

Current activities include:

  • Development of anti-CD19, anti-CD22 and anti-CD33 chimeric antigen receptor (CAR) therapy and other targeted agents and immune-based therapies
  • Novel approaches to hematopoietic stem cell transplantation, with a focus on immune restoration and treatment of patients with primary immune deficienies
  • Post-transplant allogeneic immunotherapy to direct anti-tumor responses and treatment of relapse after transplant
  • Bedside-to-bench based studies designed to support current and future clinical trials

Search our Clinical Trials: